Aelis Farma【AELIS】銘柄情報

Aelis Farma SA (AELIS) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

1.10

( -1.26% )

買値

1.082

売値

1.106

出来高

7,586

1.10 日の範囲 1.112

0.672 52 週間の範囲 2.30

時価総額

14.956M

前日終値

1.114

始値

1.10

時刻

278

1.1

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

31,537 €

発行済株式数

13,596,550

配当利回り

PER

-2.44

1 株当たり利益 (EPS)

-0.47

歳入

2.08M

純利益

-6.43M

Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is... Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase II clinical trials to treat cognitive deficits observed in down syndrome, as well as other cognitive impairments. Aelis Farma SA was incorporated in 2013 and is headquartered in Bordeaux, France. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.aelisfarma.com

本社

Bordeaux, France

設立

2026

Aelis Farma SA is listed in the Healthcare sector of the ユーロネクスト with ticker AELIS. The last closing price for Aelis Farma was 1.11 €. Over the last year, Aelis Farma shares have traded in a share price range of 0.672 € to 2.30 €.

Aelis Farma currently has 13,596,550 shares in issue. The market capitalisation of Aelis Farma is 14.96 € million. Aelis Farma has a price to earnings ratio (PE ratio) of -2.44.

Aelis Farma : Bilan semestriel du contrat de liquidité conclu avec Invest Securities

Regulatory News: Aelis Farma (ISIN : FR0014007ZB4 – Mnémonique : AELIS, éligible PEA-PME), société biopharmaceutique au stade clinique...

Aelis Farma: Availability of the Description of the Share Buyback Program

Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of...

Results of Aelis Farma Combined General Meeting of May 27, 2025

Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), clinical-stage biopharmaceutical company specializing in the development of...

Aelis Farma : Assemblée générale mixte du 27 mai 2025 : mise à disposition des documents préparatoires et modalités de participation et de vote

Regulatory News: Aelis Farma (ISIN : FR0014007ZB4 – Mnémonique : AELIS, éligible PEA-PME), société biopharmaceutique au stade clinique...

Aelis Farma : Mise à disposition du Document d’Enregistrement Universel 2024

Regulatory News: Aelis Farma (ISIN : FR0014007ZB4 – Mnémonique : AELIS, éligible PEA-PME), société biopharmaceutique au stade clinique...

Aelis Farma Reports Its 2024 Annual Financial Results and Confirms Its 2025 Outlook

2024 has been marked by several significant events: The achievement of key milestones for the Company's two drug candidates: AEF0117:...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.1	-8.33333333333	1.2	1.22	1.08	14387	1.14328471	DE
4	-0.158	-12.559618442	1.258	1.318	1.08	30457	1.21950085	DE
12	-0.09	-7.56302521008	1.19	1.8	1.08	30638	1.29321201	DE
26	-0.035	-3.08370044053	1.135	2.3	1.05	48207	1.4883335	DE
52	-0.07	-5.98290598291	1.17	2.3	0.672	43900	1.31803036	DE
156	-12.85	-92.1146953405	13.95	14	0.672	18148	1.48351264	DE
260	-12.4	-91.8518518519	13.5	14.48	0.672	12667	1.7329751	DE